v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Expenses    
Research and development expenses $ 2,043,984 $ 1,476,160
General and administrative expenses 1,184,730 717,147
Operating Loss (3,228,714) (2,193,307)
Other Income (Expense)    
Interest expense (362)
Interest income 1,583 4,940
Net Operating Loss Before Income Tax Benefit (3,227,131) (2,188,729)
Income Tax Benefit 89,248
Net Loss $ (3,227,131) $ (2,099,481)
Net Loss Per Common Share - Basic and Diluted $ (0.20) $ (0.14)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted 15,831,118 14,583,698

Source